title: Pharmacologic interactions of multidrug therapy for dyslipidemia.
abstract: Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.
authors.affiliation: Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 9 Gates Building 3400 Spruce Street, Philadelphia, PA 19103, USA. nidhi.mehta@uphs.upenn.edu
authors.forename: Nidhi
authors.initials: N
authors.lastname: Mehta
authors.forename: Emil M
authors.initials: EM
authors.lastname: deGoma
mesh_terms: D004347:Drug Interactions; D004358:Drug Therapy; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D014943:Global Health; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D015994:Incidence; D008055:Lipids / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids